The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer.

Results have historically shown a broad plasticity in the origin of tumors and their functions, with significant heterogeneity observed in both morphologies and functional capabilities. Largely unknown, however, are the mechanisms by which these variations occur and how these events influence tumor formation and behavior. Contemporary views on the origin of tumors focus mainly on the role of particular sets of driver transformations, mutational or epigenetic, with the occurrence of the observed heterogeneity as an accidental byproduct of oncogenesis. As such, we present a hypothesis that tumors form due to heterogeneous adaptive selection in response to environmental stress through intrinsic genomic sampling mechanisms. Specifically, we propose that eukaryotic cells intrinsically explore their available genomic information, the greater genomic landscape (GGL), in response to stress under normal conditions, long before the formation of a cancerous lesion. Finally, considering the influence of chromatin heterogeneity on the GGL, we propose a new class of compounds, chromatin-protective therapies (CPT), which target the physical variations in chromatin topology. In this approach, CPTs reduce the overall information space available to limit the formation of tumors or the development of drug-resistant phenotypes. Cancer Res; 76(19); 5605-9. ©2016 AACR.

[1]  Konradin Metze,et al.  Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma , 2010, BMC Cancer.

[2]  Vadim Backman,et al.  Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. , 2009, Cancer research.

[3]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[4]  N. Hay Interplay between FOXO, TOR, and Akt. , 2011, Biochimica et biophysica acta.

[5]  Vadim Backman,et al.  HDAC Up-Regulation in Early Colon Field Carcinogenesis Is Involved in Cell Tumorigenicity through Regulation of Chromatin Structure , 2013, PloS one.

[6]  J. Poderoso,et al.  Mitochondrial regulation of cell cycle and proliferation. , 2012, Antioxidants & redox signaling.

[7]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[8]  D. Rasnick Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy. , 2002, Cancer genetics and cytogenetics.

[9]  A. Feinberg,et al.  The epigenetic progenitor origin of human cancer , 2006, Nature Reviews Genetics.

[10]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[11]  D. Chandra,et al.  Mitochondrial and postmitochondrial survival signaling in cancer. , 2014, Mitochondrion.

[12]  Allon M. Klein,et al.  Clonal dynamics of native haematopoiesis , 2014, Nature.

[13]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[14]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[15]  M. Schuldiner,et al.  A novel single-cell screening platform reveals proteome plasticity during yeast stress responses , 2013, The Journal of cell biology.

[16]  Allen Taflove,et al.  Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells , 2008, Proceedings of the National Academy of Sciences.

[17]  Cheemeng Tan,et al.  Molecular crowding shapes gene expression in synthetic cellular nanosystems , 2013, Nature nanotechnology.

[18]  A. Morris,et al.  Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions , 2015, BDJ.

[19]  B. Vogelstein,et al.  Variation in cancer risk among tissues can be explained by the number of stem cell divisions , 2015, Science.

[20]  Vadim Backman,et al.  Macromolecular crowding as a regulator of gene transcription. , 2014, Biophysical journal.

[21]  C. Swanton Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.

[22]  Sasha F. Levy,et al.  Bet Hedging in Yeast by Heterogeneous, Age-Correlated Expression of a Stress Protectant , 2012, PLoS biology.

[23]  Xuemei Lu,et al.  Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution , 2015, Proceedings of the National Academy of Sciences.

[24]  K. Brown,et al.  New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers , 2015, Ecancermedicalscience.

[25]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[26]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[27]  S. Rea,et al.  The role of mitochondrial dysfunction in age-related diseases. , 2015, Biochimica et biophysica acta.

[28]  A. Shilatifard,et al.  Chromatin signatures of cancer , 2015, Genes & development.

[29]  Laura K. Bianchi,et al.  Nanoscale changes in chromatin organization represent the initial steps of tumorigenesis: a transmission electron microscopy study , 2014, BMC Cancer.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[31]  Danny R. Welch Tumor Heterogeneity--A 'Contemporary Concept' Founded on Historical Insights and Predictions. , 2016, Cancer research.